Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» BlueRock Therapeutics
BlueRock Therapeutics
Bayer christens $250M cell therapy 'launch facility' in Berkeley
Fierce Pharma
Tue, 10/10/23 - 11:55 am
Bayer
cell therapy
Berkeley
Californi
BlueRock Therapeutics
Bayer preps for phase 2 after Parkinson's cell therapy clears safety bar in early-stage study
Fierce Biotech
Mon, 08/28/23 - 11:37 am
Bayer
Parkinson's Disease
cell therapy
bemdaneprocel
BlueRock Therapeutics
Fierce Biotech Layoff Tracker 2023: Bayer-bought BlueRock makes cuts; Alaunos lets go 60% of teams
Fierce Biotech
Fri, 08/18/23 - 10:28 am
layoffs
Alaunos Therapeutics
BlueRock Therapeutics
Thermo Fisher
Bristol Myers Squibb
Atreca
Galera Therapeutics
Inovio
Salarius Pharmaceuticals
Karyopharm Therapeutics
Intergalatic Therapeutics
Bayer-bought BlueRock cuts 12% of workforce across 3 sites as pipeline contracts
Fierce Biotech
Thu, 08/17/23 - 11:32 pm
BlueRock Therapeutics
Parkinson's Disease
Bayer
layoffs
Bayer’s BlueRock inks cardiovascular cell therapy delivery deal
Fierce Pharma
Wed, 08/31/22 - 10:22 am
Bayer
BlueRock Therapeutics
heart failure
cell therapy
BioCardia
FDA gives speedy review to Bayer’s Parkinson’s stem cell therapy
Pharmaforum
Tue, 07/20/21 - 11:14 am
Bayer
BlueRock Therapeutics
FDA
DA01
stem cells
Parkinson's Disease
Bayer's billon-dollar Parkinson's disease bets land in the clinic
Fierce Biotech
Tue, 06/8/21 - 11:15 am
Bayer
Parkinson's Disease
DA01
BlueRock Therapeutics
Bayer (BAYRY) Inks Deal to Develop Therapies for Eye Diseases
Yahoo/Zacks.com
Tue, 05/18/21 - 11:15 pm
Bayer
BlueRock Therapeutics
Fujifilm Cellular Dynamics
Opsis Therapeutics
cell therapy
eye diseases
Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work
Xconomy
Thu, 08/8/19 - 12:57 pm
Bayer
Versant Ventures
cell therapy
M&A
BlueRock Therapeutics
Bayer, Versant close $225m Series A to launch stem cell company
Mass Device
Tue, 12/13/16 - 01:20 pm
Bayer
Versant Ventures
stem cells
Series A
BlueRock Therapeutics
devices
regenerative medicine